Table 3 Adverse events by day 28
Adverse events | Tocilizumab group (N = 56) | Usual care group (N = 58) |
|---|---|---|
Lobar consolidation Cardiac Event Bleeding Septic shock | 3 (5.4%) 1 (1.8%) 1 (1.8%) 0 (0%) | 2 (3.4%) 1 (1.7%) 1 (1.7%) 0 (0%) |
Adverse events | Tocilizumab group (N = 56) | Usual care group (N = 58) |
|---|---|---|
Lobar consolidation Cardiac Event Bleeding Septic shock | 3 (5.4%) 1 (1.8%) 1 (1.8%) 0 (0%) | 2 (3.4%) 1 (1.7%) 1 (1.7%) 0 (0%) |